X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Precision exercised its option to regain rights for the programs, including its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for sophisticated gene edits.
Lead Product(s): Undisclosed
Therapeutic Area: Genetic Disease Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Precision BioSciences
Deal Size: $555.0 million Upfront Cash: $100.0 million
Deal Type: Termination April 16, 2024
Details:
Under the agreement, Prevail has been granted rights to evaluate certain proprietary adeno-associated virus (AAV) capsids developed by Sangamo and may exercise certain options to license these capsids for multiple undisclosed neurological targets.
Lead Product(s): Adeno-associated Virus Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Sangamo Therapeutics
Deal Size: $1,190.0 million Upfront Cash: Undisclosed
Deal Type: Agreement July 17, 2023
Details:
Under the collaboration, Prevail gets exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified genetic targets known to cause serious neurological and neuromuscular diseases.
Lead Product(s): CRISPR-based Genetic Medicine
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Scribe Therapeutics
Deal Size: $1,575.0 million Upfront Cash: $75.0 million
Deal Type: Collaboration May 16, 2023
Details:
Delivering AAV gene therapy systemically to target the CNS, while limiting exposure to non-target organs (such as the liver), has been a significant challenge in the gene therapy field.
Lead Product(s): AAV-based Gene Therapy
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Recipient: Capsida
Deal Size: $740.0 million Upfront Cash: $55.0 million
Deal Type: Collaboration January 04, 2023
Details:
The collaboration will focus on the discovery and development of novel AAV capsids for CNS diseases. As a part of the collaboration, Prevail will receive rights to utilize one of Lacerta’s novel AAV capsids for select undisclosed CNS targets.
Lead Product(s): AAV Capsid-based Therapeutic
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Cell and Gene therapy
Recipient: Lacerta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration August 23, 2022
Details:
Acquisition will set up a gene therapy program at Lilly, based on Prevail's portfolio of neuroscience assets, including the lead candidate, PR001, and will broaden Lilly's commitment to use novel modalities to address fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition January 22, 2021
Details:
Acquisition will establish a gene therapy program at Lilly, anchored by Prevail's portfolio of neuroscience assets, and will broaden Lilly's commitment to use novel modalities to attempt to address otherwise fatal genetic forms of neurodegenerative disease.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Eli Lilly
Deal Size: $1,040.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition December 15, 2020
Details:
PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations.
Lead Product(s): PR006,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR006
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 30, 2020
Details:
The Company expects to initiate enrollment of the Phase 1/2 PROVIDE clinical trial of PR001 for Type 2 Gaucher disease patients in the fourth quarter of 2020 and currently anticipates it will provide the next update on PR001 biomarker and safety data for nGD in 2021.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 18, 2020
Details:
The Company is developing PR001 for patients with Parkinson’s disease with GBA1 mutations (PD-GBA) and neuronopathic Gaucher disease (nGD). Prevail expects to start enrollment of the PROVIDE Phase 1/2 clinical trial of PR001 in the second half of 2020.
Lead Product(s): PR001,Methylprednisolone,Sirolimus
Therapeutic Area: Neurology Product Name: PR001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
